» Articles » PMID: 18708090

Beta1 Integrin in Tissue Remodelling and Repair: from Phenomena to Concepts

Overview
Journal Pharmacol Ther
Specialty Pharmacology
Date 2008 Aug 19
PMID 18708090
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

There is substantial molecular evidence for the involvement of beta1 integrin in tissue organisation and remodelling, which confers a key role in cell growth, differentiation, migration, and survival. This role has been, in part, highlighted using the transgenic approach which does little to define the more subtle functions such as those controlled by avidity regulation. Upon activation integrins in general, including beta1 integrin, are known to exhibit global structural rearrangement and exposure of ligand binding sites. Recent evidence has revealed a role of beta1 integrin modulation in tissue repair and regeneration. The anomalies and phenomena describing the roles of beta1 integrin in tissue remodelling are reviewed, as well as the tools which have been used to define the functions of beta1 integrin and its impact on our understanding of the diverse roles of beta1 integrin in remodelling. This eclectic mix of phenomena is conceptualised to form a unified hypothesis of a novel understanding of both tissue injury and repair.

Citing Articles

Epigenome-wide analysis reveals potential biomarkers for radiation-induced toxicity risk in prostate cancer.

Lopez-Pleguezuelos C, Aguado-Barrera M, Carballo-Castro A, Peleteiro P, Calvo-Crespo P, Taboada-Valladares B Clin Epigenetics. 2025; 17(1):43.

PMID: 40050897 PMC: 11887099. DOI: 10.1186/s13148-025-01846-8.


An Integrated Dual-Layer Heterogeneous Polycaprolactone Scaffold Promotes Oral Mucosal Wound Healing through Inhibiting Bacterial Adhesion and Mediating HGF-1 Behavior.

Hong G, Hu Z, Zhou Y, Chen M, Wu H, Lu W Research (Wash D C). 2024; 7:0499.

PMID: 39691765 PMC: 11651385. DOI: 10.34133/research.0499.


Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma.

Damanakis A, Wahler I, Fuchs H, Loser H, Schroder W, Zander T Sci Rep. 2022; 12(1):20745.

PMID: 36456612 PMC: 9715537. DOI: 10.1038/s41598-022-25071-y.


Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis.

Li N, Qin Y, Dai D, Wang P, Shi M, Gao J Front Bioeng Biotechnol. 2022; 9:804415.

PMID: 35141215 PMC: 8819148. DOI: 10.3389/fbioe.2021.804415.


Fractional laser ablation for the targeted cutaneous delivery of an anti-CD29 monoclonal antibody - OS2966.

Lapteva M, Del Rio-Sancho S, Wu E, Carbonell W, Bohler C, Kalia Y Sci Rep. 2019; 9(1):1030.

PMID: 30705293 PMC: 6355906. DOI: 10.1038/s41598-018-36966-0.